Monitor EASD presentation in October for full data; near-term price action may be volatile on enthusiasm without human clinical de-risking.
Price Chart
Executive Summary
iBio reported new preclinical NHP data for its Activin E antibody candidate IBIO-610, showing 98% target inhibition at week 4 and 97% at week 8 after a single dose, and a 73% reduction in lean mass loss when combined with semaglutide. The data, which supports a potentially best-in-class, infrequent-dosing profile, will be presented at the EASD Annual Meeting in October.
Key Facts
- Single dose of IBIO-610 reduced active Activin E by 98% at week 4 and 97% at week 8 vs. baseline in obese NHPs.
- IBIO-610 combined with semaglutide drove greater visceral and total fat loss while reducing lean mass loss by 73% vs. semaglutide alone.
- Full dataset to be presented at the 62nd EASD Annual Meeting (Sept 28 – Oct 2, 2026, Milan).
- iBio market cap ~$87M, analyst consensus 92% bullish (11 out of 12 Buy/Strong Buy).
Financial Impact
No financial figures reported; preclinical data has no direct revenue or EPS impact.
Risk Factors
- Preclinical NHP data may not translate to human clinical trial results.
- Lack of financial data or cash runway disclosure; early-stage biotech carries high burn-rate risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001420720-26-000010 |
| Document: ibio-20260701xex99d1.htm | 0001420720-26-000010 |
| Document: 0001420720-26-000010-index-headers.html | 0001420720-26-000010 |
| Document: 0001420720-26-000010-index.html | 0001420720-26-000010 |
| Document: 0001420720-26-000010.txt | 0001420720-26-000010 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | 8-K | $0.8210 | awaiting T+5 | — | $0.7070 (−13.89%) |
Oct 14, 2026 12d ago | SC 13G | $0.7808 $0.8400 | ▲ +7.58% | ▲ +7.13% | $0.7070 (−9.45%) |
Oct 13, 2026 13d ago | 8-K | $0.7818 $0.8210 | ▲ +5.01% | ▲ +6.17% | $0.7070 (−9.57%) |
Sep 14, 2026 6w ago | 8-K | $1.19 $1.33 | ▲ +11.76% | ▲ +9.64% | $0.7070 (−40.59%) |
Aug 28, 2026 8w ago | 8-K | $1.36 $1.31 | ▼ −3.68% | ▼ −3.79% | $0.7070 (−48.01%) |
Aug 28, 2026 8w ago | Press Release | $1.36 $1.31 | ▼ −3.68% | ▼ −3.79% | $0.7070 (−48.01%) |
Jul 1, 2026 16w ago | 8-K | $1.75 $1.59 | ▼ −9.14% | ▼ −9.40% | $0.7070 (−59.60%) |
May 15, 2026 23w ago | 3 | $1.47 $1.84 | ▲ +25.17% | ▲ +24.21% | $0.7070 (−51.90%) |
May 12, 2026 23w ago | Press Release | $1.55 $1.50 | ▲ +3.23% | ▲ +2.07% | $0.7070 (+54.39%) |
May 8, 2026 24w ago | 8-K | $1.66 $1.42 | ▼ −14.46% | ▼ −14.37% | $0.7070 (−57.41%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers